GC Genome, a leading clinical genomics and liquid biopsy company, announced that its study analyzing cell-free DNA (cfDNA) ...
A retrospective real-world analysis presented at the 2025 ASH Annual Meeting and Exposition showed that circulating tumor DNA (ctDNA) detected at the end of treatment (EOT) was a prognostic indicator ...
A collaborative effort by the Formosa-Jordan lab from the Max Planck Institute for Plant Breeding Research in Cologne, ...
DNA nanostructures are exciting new biomedical tools with myriad potential in treatment, diagnosis and disease prevention.
A groundbreaking study introduces new noninvasive screening tools that have the potential to greatly enhance patient comfort ...
The market offers significant opportunities in non-invasive cancer diagnostics using in vitro blood tests, with potential to replace traditional biopsies. Key areas include screening, diagnosis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback